network member

Iowa

About Network Member

Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243
Columbia University Irving Medical Center
Fox Chase Cancer Center
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Iowa Holden Comprehensive Cancer Center
Currently Enrolling

HCRN-LUN21-530

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)
Cancer areas:Lung
Barbara Ann Karmanos Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Currently Enrolling

HCRN-MCC20-443

A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)
University of Iowa Holden Comprehensive Cancer Center
Weill Cornell Medicine
Currently Enrolling

BTCRC-HEM15-027

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027
Cancer areas:Lymphoma
Masonic Cancer Center, University of Minnesota
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Cancer areas:Head and Neck
Masonic Cancer Center, University of Minnesota
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Currently Enrolling

BTCRC-LUN20-462

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Cancer areas:Melanoma
Fox Chase Cancer Center
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Nebraska Cancer Specialists
Providence Cancer Institute
University of Iowa Holden Comprehensive Cancer Center
Enrollment Closed

BTCRC-BRE18-337

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
Cancer areas:Breast
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-LUN18-363

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center